Tissue factor/factor VIIa induces cell survival and gene transcription by transactivation of the insulin-like growth factor 1 receptor

Thrombosis and Haemostasis

Volumn 111, Issue 4, 2013, Pages 748-760

  Åberg, Mikael ^a   Eriksson, Oskar ^a   Mokhtari, Dariush ^a   Siegbahn, Agneta ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Apoptosis; Cell signalling; FVIIa; IGF 1R; Tissue factor

Indexed keywords

3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; BLOOD CLOTTING FACTOR 7A; CASPASE 3; CASPASE 8; MESSENGER RNA; PICROPODOPHYLLIN; PROTEIN INHIBITOR; SMALL INTERFERING RNA; SOMATOMEDIN C RECEPTOR; THROMBOPLASTIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; 2-PHENYL-2-(1-PIPERIDINYL)PROPANE; PHENCYCLIDINE; PROTEIN BINDING; TUMOR NECROSIS FACTOR ALPHA; TYRPHOSTIN;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL ISOLATION; CELL SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA ISOLATION; SIGNAL TRANSDUCTION; SUMOYLATION; TRANSACTIVATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BLOOD CLOTTING; CELL PROTECTION; DRUG EFFECTS; EPITHELIUM CELL; GENETICS; METABOLISM; MONOCYTE; PHYSIOLOGY; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

APOPTOSIS; BLOOD COAGULATION; CELL LINE, TUMOR; CELL SURVIVAL; CYTOPROTECTION; EPITHELIAL CELLS; FACTOR VIIA; HUMANS; MONOCYTES; PHENCYCLIDINE; PROTEIN BINDING; RECEPTOR CROSS-TALK; RECEPTOR, IGF TYPE 1; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; THROMBOPLASTIN; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSCRIPTIONAL ACTIVATION; TUMOR NECROSIS FACTOR-ALPHA; TYRPHOSTINS;

EID: 84897544436     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-07-0593     Document Type: Article

References (50)

1. Siddle K. Signalling by insulin and IGF receptors: supporting acts and new players. J Mol Endocrinol 2011; 47: R1-10.
2. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 2012; 12: 159-169.
3. Scartozzi M, Bianconi M, Maccaroni E, et al. State of the art and future perspectives for the use of insulin-like growth factor receptor 1 (IGF-1R) targeted treatment strategies in solid tumors. Discov Med 2011; 11: 144-153.
4. Ellison GM, Waring CD, Vicinanza C, et al. Physiological cardiac remodelling in response to endurance exercise training: cellular and molecular mechanisms. Heart 2012; 98: 5-10.
5. Smith TJ. Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases? PharmacolRev 2010; 62: 199-236.
6. Favelyukis S, Till JH, Hubbard SR, et al. Structure and autoregulation of the insulin-like growth factor 1 receptor kinase. Nat Struct Biol 2001; 8: 1058-1063.
7. Zhao D, Bakirtzi K, Zhan Y, et al. Insulin-like growth factor-1 receptor transactivation modulates the inflammatory and proliferative responses of neurotensin in human colonic epithelial cells. J Biol Chem 2011; 286: 6092-6099.
8. Tu H, Xu C, Zhang W, et al. GABAB receptor activation protects neurons from apoptosis via IGF-1 receptor transactivation. J Neurosci 2010; 30: 749-759.
9. Aleksic T, Chitnis MM, Perestenko OV, et al. Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells. Cancer Res 2010; 70: 6412-6419.
10. Sehat B, Tofigh A, Lin Y, et al. SUMOylation mediates the nuclear translocation and signaling of the IGF-1 receptor. Sci Signal 2010; 3: ra10.
11. Warsito D, Sjostrom S, Andersson S, et al. Nuclear IGF1R is a transcriptional coactivator of LEF1/TCF. EMBO Rep 2012; 13: 244-250.
12. Zioncheck TF, Roy S, Vehar GA. The cytoplasmic domain of tissue factor is phosphorylated by a protein kinase C-dependent mechanism. J Biol Chem 1992; 267: 3561-3564.
13. Mackman N, Morrissey JH, Fowler B, et al. Complete sequence of the human tissue factor gene, a highly regulated cellular receptor that initiates the coagulation protease cascade. Biochemistry 1989; 28: 1755-1762.
14. Rao LV, Pendurthi UR. Regulation of tissue factor coagulant activity on cell surfaces. J Thromb Haemost 2012; 10: 2242-2253.
15. Siegbahn A, Johnell M, Nordin A, et al. TF/FVIIa transactivate PDGFRbeta to regulate PDGF-BB-induced chemotaxis in different cell types: involvement of Src and PLC. Arterioscler Thromb Vasc Biol 2008; 28: 135-141.
16. Wiiger MT, Prydz H. The epidermal growth factor receptor (EGFR) and proline rich tyrosine kinase 2 (PYK2) are involved in tissue factor dependent factor VIIa signalling in HaCaT cells. Thromb Haemost 2004; 92: 13-22.
17. Aberg M, Siegbahn A. Tissue Factor non-coagulant signalling-molecular mechanisms and biological consequences with focus on cell migration and apoptosis. J Thromb Haemost 2013; 11: 817-825.
18. Callander NS, Varki N, Rao LV. Immunohistochemical identification of tissue factor in solid tumors. Cancer 1992; 70: 1194-1201.
19. Shigemori C, Wada H, Matsumoto K, et al. Tissue factor expression and metastatic potential of colorectal cancer. Thromb Haemost 1998; 80: 894-898.
20. Ueno T, Toi M, Koike M, et al. Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration. Br J Cancer 2000; 83: 164-170.
21. Aberg M, Johnell M, Wickstrom M, et al. Tissue Factor/ FVIIa prevents the extrinsic pathway of apoptosis by regulation of the tumor suppressor Death-Associated Protein Kinase 1 (DAPK1). Thromb Res 2011; 127: 141-148.
22. Soderberg O, Leuchowius KJ, Gullberg M, et al. Characterizing proteins and their interactions in cells and tissues using the in situ proximity ligation assay. Methods 2008; 45: 227-232.
23. Parrizas M, Gazit A, Levitzki A, et al. Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins. Endocrinology 1997; 138: 1427-1433.
24. Girnita A, Girnita L, del PF, et al. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res 2004; 64: 236-242.
25. Siegbahn A, Johnell M, Sorensen BB, et al. Regulation of chemotaxis by the cytoplasmic domain of tissue factor. Thromb Haemost 2005; 93: 27-34.
26. Peruzzi F, Prisco M, Morrione A, et al. Anti-apoptotic signaling of the insulinlike growth factor-I receptor through mitochondrial translocation of c-Raf and Nedd4. J Biol Chem 2001; 276: 25990-25996.
27. Furlanetto RW, Dey BR, Lopaczynski W, et al. 14-3-3 proteins interact with the insulin-like growth factor receptor but not the insulin receptor. Biochem J 1997; 327: 765-771.
28. Neal CL, Yu D. 14-3-3zeta as a prognostic marker and therapeutic target for cancer. Expert Opin Ther Targets 2010; 14: 1343-1354.
29. Sorensen BB, Rao LV, Tornehave D, et al. Antiapoptotic effect of coagulation factor VIIa. Blood 2003; 102: 1708-1715.
30. Tsao BP, Fair DS, Curtiss LK, et al. Monocytes can be induced by lipopolysaccharide-triggered T lymphocytes to express functional factor VII/VIIa protease activity. J Exp Med 1984; 159: 1042-1057.
31. Koizume S, Jin MS, Miyagi E, et al. Activation of cancer cell migration and invasion by ectopic synthesis of coagulation factor VII. Cancer Res 2006; 66: 9453-9460.
32. Borissoff JI, Heeneman S, Kilinc E, et al. Early atherosclerosis exhibits an enhanced procoagulant state. Circulation 2010; 122: 821-830.
33. Abroun S, Ishikawa H, Tsuyama N, et al. Receptor synergy of interleukin-6 (IL-6) and insulin-like growth factor-I in myeloma cells that highly express IL-6 receptor alpha [corrected]. Blood 2004; 103: 2291-2298.
34. Awasthi V, Mandal SK, Papanna V, et al. Modulation of tissue factor-factor VIIa signaling by lipid rafts and caveolae. Arterioscler Thromb Vasc Biol 2007; 27: 1447-1455.
35. Huo H, Guo X, Hong S, et al. Lipid rafts/caveolae are essential for insulin-like growth factor-1 receptor signaling during 3T3-L1 preadipocyte differentiation induction. J Biol Chem 2003; 278: 11561-11569.
36. Muth H, Kreis I, Zimmermann R, et al. Differential gene expression in activated monocyte-derived macrophages following binding of factor VIIa to tissue factor. Thromb Haemost 2005; 94: 1028-1034.
37. Kong W, McConalogue K, Khitin LM, et al. Luminal trypsin may regulate enterocytes through proteinase-activated receptor 2. Proc Natl Acad Sci USA 1997; 94: 8884-8889.
38. Oikonomopoulou K, Hansen KK, Saifeddine M, et al. Kallikrein-mediated cell signalling: targeting proteinase-activated receptors (PARs). Biol Chem 2006; 387: 817-824.
39. Zabel BA, Allen SJ, Kulig P, et al. Chemerin activation by serine proteases of the coagulation, fibrinolytic, and inflammatory cascades. J Biol Chem 2005; 280: 34661-34666.
40. Neal CL, Xu J, Li P, et al. Overexpression of 14-3-3zeta in cancer cells activates PI3K via binding the p85 regulatory subunit. Oncogene 2012; 31: 897-906.
41. Raper SE, Burwen SJ, Barker ME, et al. Translocation of epidermal growth factor to the hepatocyte nucleus during rat liver regeneration. Gastroenterology 1987; 92: 1243-1250.
42. Bettermann K, Benesch M, Weis S, et al. SUMOylation in carcinogenesis. Cancer Lett 2012; 316: 113-125.
43. Baake M, Doenecke D, Albig W. Characterisation of nuclear localisation signals of the four human core histones. J Cell Biochem 2001; 81: 333-346.
44. Kaouass M, Beaulieu R, Balicki D. Histonefection: Novel and potent non-viral gene delivery. J Control Release 2006; 113: 245-254.
45. Kouzarides T. Chromatin modifications and their function. Cell 2007; 128: 693-705.
46. Mahadevan LC, Willis AC, Barratt MJ. Rapid histone H3 phosphorylation in response to growth factors, phorbol esters, okadaic acid, and protein synthesis inhibitors. Cell 1991; 65: 775-783.
47. Cheung P, Tanner KG, Cheung WL, et al. Synergistic coupling of histone H3 phosphorylation and acetylation in response to epidermal growth factor stimulation. Mol Cell 2000; 5: 905-915.
48. Pan G, Ni J, Wei YF, et al. An antagonist decoy receptor and a death domaincontaining receptor for TRAIL. Science 1997; 277: 815-818.
49. Sato K, Niessner A, Kopecky SL, et al. TRAIL-expressing T cells induce apoptosis of vascular smooth muscle cells in the atherosclerotic plaque. J Exp Med 2006; 203: 239-250.
50. Yang A, Wilson NS, Ashkenazi A. Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation. Curr Opin Cell Biol 2010; 22: 837-844.